Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study

Tools

Item Type:	Article
Title:	Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study
Creators Name:	Lewczuk, P., Kamrowski-Kruck, H., Peters, O., Heuser, I., Jessen, F., Popp, J., Buerger, K., Hampel, H., Froelich, L., Wolf, S., Prinz, B., Jahn, H., Luckhaus, C., Perneczky, R., Huell, M., Schroeder, J., Kessler, H., Pantel, J., Gertz, H.J., Klafki, H.W., Koelsch, H., Reulbach, U., Esselmann, H., Maler, J.M., Bibl, M., Kornhuber, J. and Wiltfang, J.
Abstract:	In this report, we present the results of a multicenter study to test analytic and diagnostic performance of soluble forms of amyloid precursor proteins {alpha} and {beta} (sAPP{alpha} and sAPP{beta}) in the cerebrospinal fluid (CSF) of patients with different forms of dementing conditions. CSF samples were collected from 188 patients with early dementia (mini-mental state examination >or=20 in majority of cases) and mild cognitive impairment (MCI) in 12 gerontopsychiatric centers, and the clinical diagnoses were supported by neurochemical dementia diagnostic (NDD) tools: CSF amyloid{beta} peptides, Tau and phospho-Tau. sAPP{alpha} and sAPP{beta} were measured with multiplexing method based on electrochemiluminescence. sAPP{alpha} and sAPP{beta} CSF concentrations correlated with each other with very high correlation ratio (R=0.96, P<0.001). We observed highly significantly increased sAPP{alpha} and sAPP{beta} CSF concentrations in patients with NDD characteristic for Alzheimer's disease (AD) compared to those with NDD negative results. sAPP{alpha} and sAPP{beta} highly significantly separated patients with AD, whose diagnosis was supported by NDD findings (sAPP{alpha}: cutoff, 117.4 ng ml(-1), sensitivity, 68%, specificity, 85%, P<0.001; sAPP{beta}: cutoff, 181.8 ng ml(-1), sensitivity, 75%, specificity, 85%, P<0.001), from the patients clinically assessed as having other dementias and supported by NDD untypical for AD. We conclude sAPP{alpha} and sAPP{beta} might be regarded as novel promising biomarkers supporting the clinical diagnosis of AD.
Keywords:	Dementia, Alzheimer Disease, Amyloid{beta}, Amyloid Precursor Protein, Multiplexing, Cerebrospinal Fluid
Source:	Molecular Psychiatry
ISSN:	1359-4184
Publisher:	Nature Publishing Group
Volume:	15
Number:	2
Page Range:	138-145
Date:	February 2010
Official Publication:	https://doi.org/10.1038/mp.2008.84
PubMed:	View item in PubMed

Repository Staff Only: item control page